Teva Establishes Four Pillars To Prop Up Its Return-To-Growth Strategy
Austedo And Uzedy Key To Near-Term Growth
Executive Summary
New CEO Richard Francis outlined the company’s new focus on innovative brands, funded by a portion of capital reallocated from Teva’s generics business.
You may also be interested in...
Teva Says The Time Is Right For Two Big Immunology Biosimilar Launches
US market access senior VP Tom Rainey talks to Scrip about the upcoming launches of biosimilar versions of Humira and Stelara.
Teva Returns To Growth For First Time In Six Years
The company also announced plans to divest its active pharmaceutical ingredients (API) business as part of its ‘Pivot to Growth’ strategy.
A Year Of Change: Looking Back At Francis’ First Year At Teva
As part of a Generics Bulletin series focusing on some of the industry’s biggest players, we look at the changing landscape at Teva in 2023, spearheaded by the appointment of its CEO Richard Francis.